Sep 5, 2024, 12:00 AM
Sep 5, 2024, 12:00 AM

Johnson calls for investigation into Czech COVID vaccine mortality data

Right-Biased
Provocative
Highlights
  • Senator Ron Johnson has requested a review of Czech Republic data on COVID-19 vaccine mortality rates.
  • The data suggests that the Moderna vaccine may have higher all-cause mortality compared to the Pfizer-BioNTech vaccine.
  • Johnson's inquiry aims to ensure transparency and safety in vaccine administration and public health policies.
Story

Senator Ron Johnson from Wisconsin has requested an investigation into mortality data related to COVID-19 vaccines from the Czech Republic. In a letter addressed to FDA Commissioner Dr. Robert M. Califf and CDC Director Dr. Mandy K. Cohen, Johnson highlighted findings suggesting that the Moderna vaccine may be associated with increased all-cause mortality compared to the Pfizer-BioNTech vaccine. This data was translated and reviewed by philanthropist Steve Kirsch, who obtained it through a public records request, and supported by diagnostic pathologist Dr. Clare Craig. Johnson's inquiry specifically calls for a review of one-year and two-year mortality rates following vaccination, categorized by age groups, as well as mortality rates during periods of high and low COVID-19 cases. He questions the agencies' confidence in the safety of both vaccines and requests clarification on the data supporting their assessments. The FDA and CDC have acknowledged receipt of Johnson's request, with the FDA indicating that they will respond directly to the senator. The CDC has also confirmed they are working on a response. As of now, neither Moderna nor Pfizer has commented on the matter, leaving the public and health officials awaiting further information. This investigation reflects ongoing scrutiny regarding vaccine safety and efficacy, particularly as new data emerges. Johnson's actions underscore the importance of transparency and thorough examination of vaccine-related data, especially in light of public health decisions and vaccine rollout strategies.

Opinions

You've reached the end